Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06755347 in Healthy Volunteers and ITP
NCT03275740Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jul 2017
- Primary completion
- Jan 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of GL-2045 in primary immune thrombocytopenia (ITP) (5 arms), sponsored by Pfizer. Primary endpoints: Treatment-emergent Adverse Events, Laboratory Test Abnormalities and 2 more. Started Jul 2017; status: terminated.
02
Drugs
GL-2045
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03275740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275740.